Siemens Fonds Invest GmbH Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Siemens Fonds Invest GmbH grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 137.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,245 shares of the biopharmaceutical company's stock after purchasing an additional 1,880 shares during the period. Siemens Fonds Invest GmbH's holdings in Alnylam Pharmaceuticals were worth $764,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Allworth Financial LP increased its position in Alnylam Pharmaceuticals by 6.8% during the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company's stock worth $140,000 after purchasing an additional 38 shares during the period. Investment Management Corp of Ontario boosted its stake in shares of Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company's stock worth $1,670,000 after acquiring an additional 40 shares in the last quarter. Nixon Peabody Trust Co. boosted its stake in shares of Alnylam Pharmaceuticals by 1.9% during the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company's stock worth $540,000 after acquiring an additional 43 shares in the last quarter. Brevan Howard Capital Management LP boosted its stake in shares of Alnylam Pharmaceuticals by 3.4% during the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock worth $314,000 after acquiring an additional 44 shares in the last quarter. Finally, IFP Advisors Inc boosted its stake in shares of Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 47 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Up 4.0%

NASDAQ ALNY traded up $11.69 during trading hours on Friday, hitting $304.59. The company had a trading volume of 3,116,157 shares, compared to its average volume of 929,720. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $147.25 and a fifty-two week high of $306.25. The company has a market capitalization of $39.71 billion, a price-to-earnings ratio of -140.36 and a beta of 0.17. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The firm's 50 day moving average is $260.38 and its 200 day moving average is $255.08.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to analysts' expectations of $584.32 million. During the same period in the prior year, the company posted ($0.16) EPS. The company's quarterly revenue was up 20.2% compared to the same quarter last year. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on ALNY. Bank of America boosted their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Morgan Stanley reduced their target price on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research note on Friday, April 11th. Needham & Company LLC reaffirmed a "buy" rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 9th. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Finally, JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their target price for the company from $280.00 to $328.00 in a research note on Monday, March 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $319.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.